InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (9 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
9
T+90 hit rate
50%
T+90 mean return
+2.6%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by SCHLEIFER LEONARD S, Chairman & CEO. Director active across 1 company, notably Regeneron Pharmaceuticals, INC.. Aggregated, 16 filings have been recorded. Breakdown: 0 buy · 9 sells. Total volume traded: €255.2m. History available since 6 August 2021. The latest transaction was filed on 11 June 2024 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations16 total
▼
7,321 shares@ US$1,015.281.5% of flowCommon StockSEC:0001104659-24-071247:0
▼
787 shares@ US$1,015.020.2% of flowCommon StockSEC:0001883850-24-000029:0
▼
22,687 shares@ US$979.224.4% of flowCommon StockSEC:0001883850-24-000025:0
◇
203,204 shares@ US$399.6616.2% of flowCommon StockSEC:0001883850-24-000022:0
25,155 sharesCommon StockSEC:0001883850-23-000094:0
53,807 shares0Common StockSEC:0001883850-23-000069:0
4,461 shares@ US$710.050.0040% mcap0.8% of flowCommon StockSEC:0001883850-22-000038:0
2,886 shares@ US$710.010.0025% mcap0.5% of flowCommon StockSEC:0001883850-22-000036:0
239,063 shares@ US$270.4312.2% of flowCommon StockSEC:0001883850-21-000009
239,063 shares@ US$270.430.078% mcap15.7% of flowCommon StockSEC:0001883850-21-000009:0
200,000 shares@ US$650.030.15% mcap30.7% of flowCommon StockSEC:0001708138-21-000064:0
200,000 shares@ US$650.0323.9% of flowCommon StockSEC:0001708138-21-000064
171 shares@ US$615.540.0001% mcap0.0% of flowCommon StockSEC:0001708138-21-000058:0
171 shares@ US$615.540.0% of flowCommon StockSEC:0001708138-21-000058
240,000 shares@ US$52.030.014% mcap2.9% of flowCommon StockSEC:0001708138-21-000048:0
240,000 shares@ US$52.032.3% of flowCommon StockSEC:0001708138-21-000048
16 of 16 declarations
About SCHLEIFER LEONARD S
Leonard S. Schleifer is the President & CEO of REGENERON PHARMACEUTICALS, INC. He leads the company with a strong focus on innovation in the pharmaceutical field. Leonard is recognized for his ability to transform ideas into therapeutic solutions that improve patients' lives.
